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Purpose
To estimate and to compare ten-year survival rates in
unselected patients with early-onset breast cancer, with
and without a BRCA1 mutation. To identify prognostic
factors among unselected BRCA1-positive breast cancer
patients.
Patients and methods
3354 women who were diagnosed with stage I to stage IV
breast cancer, at or below 50 years of age, between January
1996 and December 2006 were contributed from 17 clini-
cal centers in Poland. All patients were offered genetic
testing for three founder mutations in BRCA1 (5382insC,
C61G, 4184delA). Information on tumour characteristics
at presentation and on treatments received was retrieved
by reviewing the medical records. Mortality and dates of
death were obtained by linkage to the vital statistics data-
base of the Polish Ministry of Administration and Internal
Affairs. Survival curves for the mutation-positive and
mutation-negative sub-cohorts were constructed using
Kaplan–Meier statistics and compared. Predictors of survi-
val were determined using the Cox proportional hazards
method.
Results
3354 patients were enrolled in the study, of whom 234
(7.0%) were found to carry a BRCA1 founder mutation.
The average age of diagnosis was 44 years (range 21 to 50
years). The ten-year survival for mutation carriers was
80.9% (95% CI 75.4% to 86.4%) and for non-carriers was
82.1% (95% CI 80.5% to 83.7%). After adjusting for other
prognostic variables, the hazard ratio associated with
carrying a BRCA1 mutation was 1.40 (95% CI: 0.99 to
1.99). Among BRCA1 mutation carriers, in the multivari-
able analysis, positive lymph node status was a strong pre-
dictor of mortality (HR = 4.6; 95% 2.1 to 10.0). Among
BRCA1 carriers with a small (< 2 cm) node-negative breast
cancer, the ten-year survival rate was 91.7% and tumour
size was not predictive of survival (HR = 1.01 for 1-2 cm
versus 0-1 cm tumors). Chemotherapy was associated with
improved survival in BRCA1 carriers (adjusted HR = 0.31;
95% CI 0.10 – 1.00) but not in non-carriers (HR = 1.69;
95% CI 0.95 to 2.99). The interaction between chemother-
apy, mutation status and survival was statistically signifi-
cant (p = 0.009).
Conclusions
The survival of women with breast cancer and a BRCA1
mutation is similar to that of patients without a BRCA1
mutation. For women with a small, node-negative breast
cancer and a BRCA1 mutation, the ten-year survival rate
was 91.7%. Among women with a BRCA1 mutation, survi-
val was better for women who received chemotherapy
than for women who did not receive chemotherapy.
Future studies should investigate what is the optimum
chemotherapy regimen.
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